{"title_page": "Flumexadol", "text_new": "{{Drugbox\n| Verifiedfields = \n| Watchedfields = \n| verifiedrevid = \n| IUPAC_name = 2-(3-(Trifluoromethyl)phenyl)morpholine\n| image = Flumexadol_structure.svg\n| width =\n\n<!--Clinical data-->\n| tradename = \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B            / C / D / X -->\n| pregnancy_category = \n| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->\n| legal_CA = \n| legal_UK = \n| legal_US = \n| legal_status = \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability = \n| protein_bound = \n| metabolism = \n| elimination_half-life = \n| excretion =\n\n<!--Identifiers-->\n| CAS_number_Ref = \n| CAS_number = 30914-89-7\n| CAS_supplemental = \n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = V9783UEL0F\n| ATC_prefix = None\n| ATC_suffix = \n| PubChem = 65774\n| DrugBank_Ref = \n| DrugBank = \n| ChemSpiderID_Ref = \n| ChemSpiderID = 59194\n\n<!--Chemical data-->\n| C=11 | H=12 | F=3 | N=1 | O=1\n| molecular_weight = 231.21429 g/mol\n| smiles = C1COC(CN1)C2=CC(=CC=C2)C(F)(F)F\n| StdInChI = 1S/C11H12F3NO/c12-11(13,14)9-3-1-2-8(6-9)10-7-15-4-5-16-10/h1-3,6,10,15H,4-5,7H2\n| StdInChIKey = GXPYCYWPUGKQIJ-UHFFFAOYSA-N\n| synonyms = \n}}\n\n'''Flumexadol''' ([[International Nonproprietary Name|INN]]) (developmental code name '''CERM-1841''' or '''1841-CERM''') is a [[drug]] described and researched as a non-[[opioid]] [[analgesic]] which was never marketed.<ref name=\"Elks2014a\">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA561|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=561\u2013}}</ref><ref name=\"pmid312104\">{{cite journal | vauthors = Hache J, Diamantis W, Sofia D, Streichenberger G | title = The pharmacology of 1841 CERM, a new analgesic | journal = Arzneimittelforschung | volume = 28 | issue = 4 | pages = 642\u20135 | year = 1978 | pmid = 312104 | doi = | url = }}</ref><ref name=\"KucharczykYang1979\">{{cite journal|last1=Kucharczyk|first1=N.|last2=Yang|first2=J. T.|last3=Valia|first3=K. H.|last4=Stiefel|first4=F. J.|last5=Sofia|first5=R. D.|title=Metabolites of 2-(3-Trifluoromethylphenyl)Tetrahydro-1,4-Oxazine (Cerm 1841) in Rats and Dogs|journal=Xenobiotica|volume=9|issue=11|year=1979|pages=703\u2013711|issn=0049-8254|doi=10.3109/00498257909042338}}</ref><ref name=\"Nilsson2006\">{{cite journal|last1=Nilsson|first1=Bj\u00f6rn M.|title=5-Hydroxytryptamine 2C (5-HT2C) Receptor Agonists as Potential Antiobesity Agents|journal=Journal of Medicinal Chemistry|volume=49|issue=14|year=2006|pages=4023\u20134034|issn=0022-2623|doi=10.1021/jm058240i|pmid=16821762}}</ref> It has been found to act as an [[receptor agonist|agonist]] of the [[serotonin]] [[5-HT1A receptor|5-HT<sub>1A</sub>]] (pK<sub>i</sub> = 7.1) and [[5-HT2C receptor|5-HT<sub>2C</sub>]] (pK<sub>i</sub> = 7.5) [[receptor (biochemistry)|receptor]]s and, to a much lesser extent, of the [[5-HT2A receptor|5-HT<sub>2A</sub>]] (pK<sub>i</sub> = 6.0) receptor.<ref name=\"B\u00e9gu\u00e9Bonnet-Delpon2008\">{{cite book|author1=Jean-Pierre B\u00e9gu\u00e9|author2=Daniele Bonnet-Delpon|title=Bioorganic and Medicinal Chemistry of Fluorine|url=https://books.google.com/books?id=QMVSvZ-R7I0C&pg=PA303|date=2 June 2008|publisher=John Wiley & Sons|isbn=978-0-470-28187-1|pages=303\u2013}}</ref><ref name=\"pmid16160946\">{{cite journal | author = Leysen DC | title = Selective 5-HT2C agonists as potential antidepressants | journal = IDrugs : the Investigational Drugs Journal | volume = 2 | issue = 2 | pages = 109\u201320 |date=February 1999 | pmid = 16160946 | doi = | url = }}</ref> According to Nilsson (2006) in a paper on 5-HT<sub>2C</sub> receptor agonists as potential [[anorectic]]s, \"The (+)-enantiomer of this compound showed [...] affinity for the 5-HT<sub>2C</sub> receptor (K<sub>i</sub>) 25 nM) [...] and was 40-fold selective over the 5-HT<sub>2A</sub> receptor in receptor binding studies. Curiously, the racemic version [...], also known as 1841 CERM, was originally reported to possess analgesic properties while no association with 5-HT<sub>2C</sub> receptor activity was mentioned.\"<ref name=\"Nilsson2006\" /> It is implied that flumexadol might be employable as an anorectic in addition to analgesic.<ref name=\"Nilsson2006\" /> Though flumexadol itself has never been approved for medical use, [[oxaflozane]] (brand name Conflictan) is a [[prodrug]] of the compound that was formerly used clinically in [[France]] as an [[antidepressant]] and [[anxiolytic]] agent.<ref name=\"B\u00e9gu\u00e9Bonnet-Delpon2008\" /><ref name=\"Elks2014b\">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA909|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=909\u2013}}</ref><ref name=\"isbn3-88763-075-0\">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | page = 766 | isbn = 3-88763-075-0 | oclc = | doi = | url = https://books.google.com/books?id=5GpcTQD_L2oC&lpg=PA766&dq=oxaflozane%20conflictan&as_brr=3&pg=PA766#v=onepage&q=&f=false}}</ref>\n\n==See also==\n*[[Oxaflozane]]\n* [[Befiradol]]\n* [[Fenfluramine]]\n* [[Fludorex]]\n* [[Fluminorex]]\n* [[Trifluoromethylphenylpiperazine|TFMPP]]\n\n==References==\n{{Reflist|2}}\n\n{{Serotonergics}}\n\n[[Category:5-HT1A agonists]]\n[[Category:5-HT2A agonists]]\n[[Category:5-HT2C agonists]]\n[[Category:Analgesics]]\n[[Category:Anorectics]]\n[[Category:Antidepressants]]\n[[Category:Anxiolytics]]\n[[Category:Morpholines]]\n[[Category:Trifluoromethyl compounds]]\n\n\n{{analgesic-stub}}\n", "text_old": "{{Drugbox\n| Verifiedfields = \n| Watchedfields = \n| verifiedrevid = \n| IUPAC_name = 2-(3-(Trifluoromethyl)phenyl)morpholine\n| image = Flumexadol_structure.svg\n| width =\n\n<!--Clinical data-->\n| tradename = \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B            / C / D / X -->\n| pregnancy_category = \n| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->\n| legal_CA = \n| legal_UK = \n| legal_US = \n| legal_status = \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability = \n| protein_bound = \n| metabolism = \n| elimination_half-life = \n| excretion =\n\n<!--Identifiers-->\n| CAS_number_Ref = \n| CAS_number = 30914-89-7\n| CAS_supplemental = \n| ATC_prefix = None\n| ATC_suffix = \n| PubChem = 65774\n| DrugBank_Ref = \n| DrugBank = \n| ChemSpiderID_Ref = \n| ChemSpiderID = 59194\n\n<!--Chemical data-->\n| C=11 | H=12 | F=3 | N=1 | O=1\n| molecular_weight = 231.21429 g/mol\n| smiles = C1COC(CN1)C2=CC(=CC=C2)C(F)(F)F\n| StdInChI = 1S/C11H12F3NO/c12-11(13,14)9-3-1-2-8(6-9)10-7-15-4-5-16-10/h1-3,6,10,15H,4-5,7H2\n| StdInChIKey = GXPYCYWPUGKQIJ-UHFFFAOYSA-N\n| synonyms = \n}}\n\n'''Flumexadol''' ([[International Nonproprietary Name|INN]]) (developmental code name '''CERM-1841''' or '''1841-CERM''') is a [[drug]] described and researched as a non-[[opioid]] [[analgesic]] which was never marketed.<ref name=\"Elks2014a\">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA561|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=561\u2013}}</ref><ref name=\"pmid312104\">{{cite journal | vauthors = Hache J, Diamantis W, Sofia D, Streichenberger G | title = The pharmacology of 1841 CERM, a new analgesic | journal = Arzneimittelforschung | volume = 28 | issue = 4 | pages = 642\u20135 | year = 1978 | pmid = 312104 | doi = | url = }}</ref><ref name=\"KucharczykYang1979\">{{cite journal|last1=Kucharczyk|first1=N.|last2=Yang|first2=J. T.|last3=Valia|first3=K. H.|last4=Stiefel|first4=F. J.|last5=Sofia|first5=R. D.|title=Metabolites of 2-(3-Trifluoromethylphenyl)Tetrahydro-1,4-Oxazine (Cerm 1841) in Rats and Dogs|journal=Xenobiotica|volume=9|issue=11|year=1979|pages=703\u2013711|issn=0049-8254|doi=10.3109/00498257909042338}}</ref><ref name=\"Nilsson2006\">{{cite journal|last1=Nilsson|first1=Bj\u00f6rn M.|title=5-Hydroxytryptamine 2C (5-HT2C) Receptor Agonists as Potential Antiobesity Agents|journal=Journal of Medicinal Chemistry|volume=49|issue=14|year=2006|pages=4023\u20134034|issn=0022-2623|doi=10.1021/jm058240i|pmid=16821762}}</ref> It has been found to act as an [[receptor agonist|agonist]] of the [[serotonin]] [[5-HT1A receptor|5-HT<sub>1A</sub>]] (pK<sub>i</sub> = 7.1) and [[5-HT2C receptor|5-HT<sub>2C</sub>]] (pK<sub>i</sub> = 7.5) [[receptor (biochemistry)|receptor]]s and, to a much lesser extent, of the [[5-HT2A receptor|5-HT<sub>2A</sub>]] (pK<sub>i</sub> = 6.0) receptor.<ref name=\"B\u00e9gu\u00e9Bonnet-Delpon2008\">{{cite book|author1=Jean-Pierre B\u00e9gu\u00e9|author2=Daniele Bonnet-Delpon|title=Bioorganic and Medicinal Chemistry of Fluorine|url=https://books.google.com/books?id=QMVSvZ-R7I0C&pg=PA303|date=2 June 2008|publisher=John Wiley & Sons|isbn=978-0-470-28187-1|pages=303\u2013}}</ref><ref name=\"pmid16160946\">{{cite journal | author = Leysen DC | title = Selective 5-HT2C agonists as potential antidepressants | journal = IDrugs : the Investigational Drugs Journal | volume = 2 | issue = 2 | pages = 109\u201320 |date=February 1999 | pmid = 16160946 | doi = | url = }}</ref> According to Nilsson (2006) in a paper on 5-HT<sub>2C</sub> receptor agonists as potential [[anorectic]]s, \"The (+)-enantiomer of this compound showed [...] affinity for the 5-HT<sub>2C</sub> receptor (K<sub>i</sub>) 25 nM) [...] and was 40-fold selective over the 5-HT<sub>2A</sub> receptor in receptor binding studies. Curiously, the racemic version [...], also known as 1841 CERM, was originally reported to possess analgesic properties while no association with 5-HT<sub>2C</sub> receptor activity was mentioned.\"<ref name=\"Nilsson2006\" /> It is implied that flumexadol might be employable as an anorectic in addition to analgesic.<ref name=\"Nilsson2006\" /> Though flumexadol itself has never been approved for medical use, [[oxaflozane]] (brand name Conflictan) is a [[prodrug]] of the compound that was formerly used clinically in [[France]] as an [[antidepressant]] and [[anxiolytic]] agent.<ref name=\"B\u00e9gu\u00e9Bonnet-Delpon2008\" /><ref name=\"Elks2014b\">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA909|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=909\u2013}}</ref><ref name=\"isbn3-88763-075-0\">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | page = 766 | isbn = 3-88763-075-0 | oclc = | doi = | url = https://books.google.com/books?id=5GpcTQD_L2oC&lpg=PA766&dq=oxaflozane%20conflictan&as_brr=3&pg=PA766#v=onepage&q=&f=false}}</ref>\n\n==See also==\n*[[Oxaflozane]]\n* [[Befiradol]]\n* [[Fenfluramine]]\n* [[Fludorex]]\n* [[Fluminorex]]\n* [[Trifluoromethylphenylpiperazine|TFMPP]]\n\n==References==\n{{Reflist|2}}\n\n{{Serotonergics}}\n\n[[Category:5-HT1A agonists]]\n[[Category:5-HT2A agonists]]\n[[Category:5-HT2C agonists]]\n[[Category:Analgesics]]\n[[Category:Anorectics]]\n[[Category:Antidepressants]]\n[[Category:Anxiolytics]]\n[[Category:Morpholines]]\n[[Category:Trifluoromethyl compounds]]\n\n\n{{analgesic-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Flumexadol"}
